Effectiveness And Safety Of Dalteparin In Patients With Acute Coronary Syndromes Without ST Elevations In Clinical Practice

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Pfizer

ClinicalTrials.gov Identifier:

NCT00922766

First received: June 16, 2009

Last updated: January 19, 2012

Last verified: January 2012

History of Changes

Results First Received: October 7, 2011

Study Type:	Observational
Study Design:	Observational Model: Case-Only; Time Perspective: Prospective
Condition:	Acute Coronary Syndrome
Intervention:	Drug: Dalteparin

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
A total of 618 participants were screened, of which 617 participant were assigned to study treatment and 1 participant was excluded based on investigator's discretion.

Reporting Groups

	Description
Dalteparin	Dalteparin Sodium 120 international units/kilogram (IU/kg) total body weight up to a maximum dose of 10,000 IU subcutaneously (s.c.) every 12 hours, for 1-2 weeks.

Participant Flow: Overall Study

	Dalteparin
STARTED	617
COMPLETED	610
NOT COMPLETED	7
Death	3
Withdrawal by Subject	2
Unspecified	1
Adverse Event	1

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Dalteparin	Dalteparin Sodium 120 international units/kilogram (IU/kg) total body weight up to a maximum dose of 10,000 IU subcutaneously (s.c.) every 12 hours, for 1-2 weeks.

Baseline Measures

	Dalteparin
Number of Participants [units: participants]	617
Age [units: years] Mean ± Standard Deviation	57.5 ± 12.6
Gender [units: participants]
Female	249
Male	368

Outcome Measures

Show All Outcome Measures

1. Primary:

Number of Participants With Death or Myocardial Infarction (MI) [ Time Frame: Baseline to 28 days after last dose of study drug ]

Show Outcome Measure 1

2. Primary:

Number of Participants With Major Bleeding Events [ Time Frame: Baseline to 28 days after last dose of study drug ]

Show Outcome Measure 2

3. Primary:

Number of Participants With Minor Bleeding Events [ Time Frame: Baseline to 28 days after last dose of study drug ]

Show Outcome Measure 3

4. Other Pre-specified:

Number of Participants With Stroke [ Time Frame: Baseline to 28 days after last dose of study drug ]

Show Outcome Measure 4

5. Other Pre-specified:

Number of Participants With Cardiac Arrest- Resuscitated [ Time Frame: Baseline to 28 days after last dose of study drug ]

Show Outcome Measure 5

6. Other Pre-specified:

Number of Participants With Heparin Induced Thrombocytopenia [ Time Frame: Baseline to 28 days after last dose of study drug ]

Hide Outcome Measure 6

Measure Type	Other Pre-specified
Measure Title	Number of Participants With Heparin Induced Thrombocytopenia
Measure Description	Thrombocytopenia was defined as a disorder in which there is an abnormally low platelet count. A normal platelet count ranged from 150,000 to 450,000 platelets per micro liter of blood.
Time Frame	Baseline to 28 days after last dose of study drug
Safety Issue	Yes

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
FAS included all enrolled participants who received at least 1 dose of the study medication.

Reporting Groups

	Description
Dalteparin	Dalteparin Sodium 120 international units/kilogram (IU/kg) total body weight up to a maximum dose of 10,000 IU subcutaneously (s.c.) every 12 hours, for 1-2 weeks.

Measured Values

	Dalteparin
Number of Participants Analyzed [units: participants]	617
Number of Participants With Heparin Induced Thrombocytopenia [units: Participants]	0

No statistical analysis provided for Number of Participants With Heparin Induced Thrombocytopenia

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: Pfizer ClinicalTrials.gov Call Center
Organization: Pfizer, Inc.
phone: 1-800-718-1021
e-mail: ClinicalTrials.gov_Inquiries@pfizer.com

No publications provided

Responsible Party:	Pfizer
ClinicalTrials.gov Identifier:	NCT00922766 History of Changes
Other Study ID Numbers:	A6301088
Study First Received:	June 16, 2009
Results First Received:	October 7, 2011
Last Updated:	January 19, 2012
Health Authority:	India: Institutional Review Board

To Top